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The current research status of normal tension 
glaucoma
Abstract: Normal tension glaucoma (NTG) is a progressive optic neuropathy that mimics 
primary open-angle glaucoma, but lacks the findings of elevated intraocular pressure or other 
mitigating factors that can lead to optic neuropathy. The present review summarized the causes, 
genetics, and mechanisms underlying NTG in both animal models and human patients. We also 
proposed that the neurovascular unit is a therapeutic target for NTG management.
Keywords: aging, genetics, neurovascular unit, primary open-angle glaucoma, treatment
Clinical aspects
Normal tension glaucoma (NTG) is a progressive optic neuropathy that mimics pri-
mary open-angle glaucoma (POAG), but lacks the findings of elevated intraocular 
pressure (IOP) or other mitigating factors that can lead to optic neuropathy.1 The main 
clinical features include normal angles on gonioscopy, cupping of the optic nerve, 
and visual field loss correlated with cupping that shows the progressive damage of 
the optic nerve.1–3
Epidemiologically, several risk factors have been shown to be related to NTG, the 
first of which is age. The mean age in years of patients with NTG reported in many 
studies is in the 60s.1,4 The second risk factor is sex. Some studies have suggested 
that there is a greater population of women with NTG than men;4 however, this phe-
nomenon may be due to the longer life span of females compared to males.5 The third 
risk factor is race. The incidence of NTG in different populations is not the same. It 
has been reported that there is a higher incidence of NTG in Asian populations, such 
as Japanese, compared to European populations. As many as two-thirds of glaucoma 
instances in Japan may be NTG.6 Although the relationship between NTG and other 
diseases is not clear, some systemic diseases have been reported to concur with NTG, 
such as vascular disease, migraine, vasospasm, and immune-related diseases.2 The 
diagnosis of NTG is a kind of exclusion, which means that the diagnosis is used to 
exclude other possible etiologies of optic nerve cupping with or without visual field 
loss when NTG is suspected. The first step in diagnosis is to rule out chronic anemia, 
cardiopathies, acute blood loss, episodes of systemic hypotension, decreased cerebral 
blood flow, blood dysplasias, neurosyphilis, etc, from the medical history. The second 
step in diagnosis is to rule out other glaucomas through a reliable IOP reading, angle 
examination by gonioscopy, and the status of fundus. The third step in diagnosis is to 
perform visual field (VF) testing to confirm whether there are specific glaucomatous 
VF defects.7 
For the management of NTG, the initial approach is to observe if there is any docu-
mented progression of the disease, which includes the following  indications: 1) signs 
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of change of retinal nerve fiber layer, optic peri-papilla, and 
visual fields; 2) family history of NTG with rapid progression; 
3) visual symptoms suspected to have had any progression; 
and 4) recurrent optic disc hemorrhages.4 Although there is 
no elevation of IOP in NTG, IOP reduction is considered 
the essential treatment. It has been reported that a 25%–30% 
reduction of IOP from baseline is the initial target to slow the 
disease.4 However, another report suggested that, even with a 
30% reduction of IOP, progress still occurred in a significant 
proportion of cases (40% after 4 years).8 Therefore, other 
IOP-independent treatments are needed. Calcium-channel 
blockers have been used in a clinical study to increase optic 
nerve head perfusion. Recently, the neuroprotection approach 
has been introduced to rescue the survival of neurons in 
neurodegenerative diseases of the eye and brain, including 
glaucoma. Many agents are considered promising in animal 
studies, although there is not yet reliable evidence to show 
that they are beneficial to human patients.9
The basic research and clinical 
investigations of NTG
Genetics of NTG
Etiologically, the genetic background of most types of 
glaucoma is complex. However, many ongoing studies have 
shown the inherited trait with some gene mutation in NTG 
patients. Scanning for gene mutation and association with 
NTG will benefit the understanding of the specific function 
of the genes involved in the mechanism of NTG. Below are 
listed some of the identified genes and their related functions 
in the development of NTG. 
A polymorphism of the endothelin receptor A gene has 
been found to be associated with NTG,10,11 which suggests 
the involvement of endothelin-1 (ET-1) signaling pathways 
in the development of NTG. Optic atrophy type 1 (OPA1) 
gene is reported to be related to NTG.12 It has been suggested 
that the mitochondrial OPA1 could provide defense of retinal 
ganglion cells (RGCs) from pressure-mediated retinal dam-
age.13 Altered OPA1 gene expression could directly induce 
apoptotic cell death in cultured RGC-5 cells.14 Mutation in 
the optineurin (OPTN) gene was reported to be associated 
with NTG in the hereditary POAG family.15 The functional 
role of OPTN, as described in the literature, included nuclear 
factor kappa B regulation, vesicular trafficking, immune 
response, etc. The mutated OPTN gene could induce mutation 
of E50K and H486R genes, resulting in death of RGC-5 cells 
by weakness of antioxidation.16 There have been reports of 
increasing candidate-gene alterations in the NTG population 
worldwide, such as p53 gene,17 TLR4,18 MFN1,19 MFN2,19 
PARL,19 GLC1F,20 SRBD1,21 and ELOVL5.21 These reports 
indicate that all of the gene alterations should be due to 
IOP-independent factors that are involved in some specific 
signaling pathway to target the degenerating events of RGCs 
or their axons in the development of NTG. 
As of now, some of these genes have already been 
investigated, and clear gene functions, which have been con-
firmed with studies using tissue culture and animal models, 
have been identified; others have been recently discovered 
and do not yet have a clearly identified gene function. 
However, for many of the genes, these is still a lack of large 
demographic data that would support their classification as 
major risk factors for developing NTG. Future investigations 
will continue to identify more new genes, and will clarify 
the roles of the mutated genes and the relationship that they 
have with the outside environment.
Animal models related  
to the development of NTG
As many gene mutations have already been reported to be 
associated with NTG in demographic studies, increasing 
reports on transgenic mice with the phenotypes related to 
human glaucoma have been published (Table 1).22–24 On the 
other hand, there are still many published NTG mouse mod-
els without confirmed genetic relation to human NTG.25–28,30 
However, all studies are helpful in understanding the patho-
genesis of NTG. Recent discoveries from studies of these 
transgenic mice are listed below. 
OPTN gene mutation was one of the reported NTG-
associated genes.16 Correspondingly, the transgenic mice with 
over-expression of OPTN (containing E50K point mutants) 
showed significant retinal degeneration.22 OPA1 is another 
reported human NTG-causing gene. OPA1 gene-mutated 
mice were showed with loss of RGCs, optic nerve atrophy, 
and abnormal visually evoked potential.23 WD repeat-contain-
ing protein 36 (WDR36)24 has been identified as being associ-
ated with POAG.29 It was reported that the mutant WDR36 
could directly affect the axon growth of RGCs, leading to 
progressive retinal degeneration in mice.24 
There are some transgenic mice for which the gene muta-
tions have not been reported to be related to human NTG, but 
that hold the similar phenotypes. These include glutamate/
aspartate transporter-deficient mice, which lack glutamate trans-
porters glutamate/aspartate transporter,26 and excitatory amino 
acid carrier 1-deficient mice.27 More recently, some Alzheimer’s 
disease (AD)-related transgenic mice, such as P301 mice28 and 
APP/PS1 (amyloid precursor protein/ presenilin 1) mice,25 
have been reported to have RGC loss and axonopathy without 
elevated IOP. These mice will be useful in understanding the 
AD-like pathogenic mechanisms in glaucoma and NTG. 
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Due to the large amount of clinical evidence for the 
association of ischemic optic neuropathy with NTG,4,30 there 
is an over-expression of ET-1 experimental induced animal 
model related to the development of NTG that is mainly 
focused on the ischemic-associated mechanisms. Utilizing 
microapplication of ET-1, Cioffi et al32 developed a chronic 
optic nerve ischemia model in monkeys. Optic neuropathy 
with associated optic nerve cupping was produced using 
a similar method in rabbit eyes that could resemble the 
clinical findings in NTG. To date, extraneous application of 
ET-1 to induce ischemic optic neuropathy has been reported 
in many kinds of animals, such as Rhesus monkeys, rabbits, 
and SD rats, with administration of different dosages and 
through different methods of administration.32–35 However, 
extraneous delivery of ET-1 does not fully mimic the real 
effect of the stable and persistent endogenous functions 
produced by animals. After all, NTG is a kind of chronic 
disease, which affects the elderly more than the young. 
Investigation on the long-term effect of overexpression of 
ET-1 may provide insight into the mechanism of NTG. Our 
previous study reported that NTG-like retinal degeneration 
appeared progressively more with age in transgenic mice, 
with over-expression of ET-1 in vascular endothelial cells 
(TET-1 mice). The phenotype of TET-1 mice involves 
major morphological changes, including the loss of RGCs, 
degeneration of optic axons, blood vessel changes, and reti-
nal gliosis, which was helpful in understanding the effect 
of long-term exposure of endothelial ET-1 in glaucoma and 
other vascular-related retinal degeneration.30
The role of ocular blood flow (OBF)  
in NTG
The relationship of OBF, blood pressure (BP), and NTG 
is an important topic in this area of research. High BP is a 
risk factor in high-tension glaucoma (HTG), as is evidenced 
by the positive correlation between systolic BP and IOP.37 
On the other hand, low BP, especially the nocturnal drop of 
BP, has been shown to have a greater prevalence in those with 
NTG.38,39 Low BP will decrease ocular perfusion pressure by 
the dynamic formula of pressure,40 where the corresponding 
Table 1 NTG-related models of transgenic mice
Name of mice IOP condition Gene background Characteristics of the eye Reference
TeT-1 mice Normal Overexpression of endothelin-1 
in vascular endothelial cells
RGC loss; axonal 
degeneration; BRB damage
Mi et al30
e50K mice Normal Overexpression of OPTN 
e50K gene 
Retinal degeneration;  
16-month old
Chi et al22
OPA1 mice Normal OPA1 gene mutation Loss of RGCs; optic nerve 
atrophy and abnormal 
visually evoked potential; 
degeneration from the soma 
toward the axon; 2-year old
Heiduschka et al23
wDR36 mice Normal Mutant wdr36 cDNA Directly affects axon 
growth of RGCs leading 
to progressive retinal 
degeneration; 16-month old
Chi et al24
GLAST-/- mice 
(GLAST-deficient 
mice)
Normal GLAST (one of glutamate 
transporters) deficient in  
Müller cells
Demonstrate spontaneous 
RGC and optic nerve 
degeneration without 
elevated IOP; 8-month old
Harada et al26
eAAC1-/- mice 
(EAAC1-deficient 
mice)
Normal EAACI (one of glutamate 
transporters) deficient in RGCs
Spontaneous RGC and optic
nerve degeneration without 
elevated IOP; 8-month old
Namekata et al27
Human P301S 
tau transgenic 
mice
Normal Homozygous and heterozygous 
mice transgenic for human 
P301S tau overexpression  
in neurons 
RGC loss; axonopathy; 
5-month old
Gasparini et al28
APP/PS1 mice Normal Double-transgene APP and PS1 
overexpression in neurons
APP; A-beta in neuron; 
TUNeL-RGC; MCP-1 
response; 27-month old
Ning et al25
Abbreviations: BRB, blood–retinal barrier; EAAC1, excitatory amino acid carrier 1; GLAST, glutamate/aspartate transporter; IOP, intraocular pressure; NTG, normal 
 tension glaucoma; RGC, retinal ganglion cell; APP, amyloid precursor protein; PS1, presenilin 1; OPTN, optineurin; OPA1, Optic atrophy type 1.
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result is the reduction of OBF, and thus increases the risk of 
development or progression of NTG.
Assessing OBF is important in evaluating its role in NTG; 
however, because the blood supply to the back segment of 
the eye comes from two sets of vascular systems (the retinal 
and the choroidal system), measurement of OBF is difficult. 
To date, there is not a single comprehensive technique to 
assess OBF. Different measurements provide different details 
of vascular parameters, and can be interpreted differently. 
Thus, accuracy and multifunction are the trends of the pro-
spective application of current OBF assessment approaches. 
Flammer et al41 summarized the OBF measuring techniques 
that applied in clinic and animal research. Below are listed 
some updated OBF tools and their applications. 
The most popular method in clinical settings is color Dop-
pler imaging. It is used to assess the blood flow velocity of 
retrobulbar vessels using resistivity index as the parameter. A 
higher value of resistivity index represents greater resistance 
of vasculature, indicating deleterious significance.42 Lack of 
quantification of vessel diameter in this method limits the 
application in terms of assessing OBF directly. Another device 
is the Langham OBF system, which measures pulsatile OBF 
of choroidal perfusion by monitoring the rhythmic change 
of IOP during the cardiac cycle.43 Combining the technique 
of confocal scanning laser tomography with laser Doppler 
flowmetry, the method of confocal scanning laser Doppler 
flowmetry, or Heidelberg retinal flowmetry, can assess the 
capillary blood flow of inner retinal layers and the optic disk.44 
Angiography, including fluorescein fundus angiography and 
indocyanine green, can provide information on velocity of 
blood flow in the retina and choroid by visualizing perfusion 
of ocular vessels.45 The Canon laser Doppler blood flowmeter 
(Canon Inc., Tokyo, Japan) provides assessments of both ves-
sel diameter and blood speed of retinal blood flow.46 Color 
Doppler optical coherence tomography couples the protocols 
of color Doppler with those of optical coherence tomography 
and provides analysis of the speed of OBF within the visual-
ized eye tissue.47 The updated retinal oximeters provide con-
venient assessment of retinal vessel oxygenation associated 
with a pseudocolor fundus image and are easier to perform, 
however, not all oximeters can measure OBF.48 
There are many other approaches still used in clinic set-
tings to assess different parts of ocular vasculature and to 
indicate particular information related to OBF (eg, the laser 
speckle phenomenon49 and the blue field entoptic technique).50 
The general limitation of these techniques is their single 
function, which cannot provide as much information as the 
other multifunctional instruments described above.
Experimental methods are important in investigating 
the role of OBF in the mechanism of glaucoma in animals. 
The above assessments can also be used as nonintrusive 
techniques on living animals; however, in some small-sized 
animals, such as rodents, many of the methods are not vali-
dated. The methods used currently for rodents include the 
microsphere method51 to detect the relative intensity of OBF, 
vascular casting techniques,52 and the ink-perfusion method.53 
Vascular casting techniques and the ink-perfusion method 
are aimed at visualizing the alteration of retinal vasculature 
in order to reflect the change of OBF. Overall, even if there 
has been no uniform standard to date, different methods 
could still provide much detailed information related to the 
alteration of OBF in NTG.43
In summary, OBF has various roles in NTG: 1) OBF is an 
indicator for evaluating vascular dysregulation; 2) reduction 
of OBF suggests the presence of ischemic mechanism 
in NTG patients; and 3) assessment of OBF can be used as 
an indicator in vascular protective therapy in NTG.
IOP-independent mechanisms in NTG
The damaging factors involved in NTG
Although IOP plays a predominant role in glaucoma, either 
in HTG or NTG, IOP-independent factors (such as oxidative 
stress, glutamate toxicity, vascular factors, etc) still play 
important roles in the development of NTG. Among IOP-
independent, vascular factors have been most attended 
to.54 Further, these vascular factors have been classified 
as either systemic vascular risk factors, such as nocturnal 
hypotension and vasospasm, or local risk factors, such as 
disc hemorrhages, peripapillary atrophy, and choroidal 
sclerosis.55,56 The latter classification is considered to be more 
important than the former, for a more direct relationship 
with the glaucomatous process.57 The presence of decreased 
OBF in NTG patients3 and the prevalent incidence of NTG 
among those with vasospasm55,56 provide overwhelming 
evidences to indicate the significance of vascular factors in 
the development or progression of NTG. Flammer58 uses the 
term “vascular dysregulation” in reference to the mechanism 
of glaucoma, and suggested that vascular dysregulation as an 
initial damage in the mechanism of NTG,59 which led to the 
unstable OBF in NTG.59 Vascular dysregulation increases the 
impact of ischemia, affecting not only retinal tissue but also 
the optic nerve, and contributes to the degeneration of RGCs 
and their axons. Under the conditions of ischemia, many 
vascular-related factors have been shown to be involved in the 
pathogenesis of NTG, eg, oxidative stress, ET-1, glutamine, 
vasogenic cytokines, etc.60 
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Aging is another important risk factor in demographic 
studies of glaucoma,2 especially in NTG.30,61 With regard to 
senescence, glaucoma has been considered an age-related 
disease. With regard to cytology, aging has been proposed 
to play a role in contributing to the damage of nuclear 
and mitochondrial DNA in mammals.62 Many clinical and 
experimental findings have shown that aging-related factors 
are involved in the mechanism of glaucoma. Amyloid-β 
(Aβ), the major neuronal toxic factor in AD, is one of the 
molecular links between glaucoma and neurodegenerative 
disease of central nervous system. Recently, expression of 
Aβ and amyloid precursor protein (APP) was observed in the 
retina and optic nerve in experiment-induced chronic ocular 
hypertension rats,63 chronic ocular hypertension mice,64 and 
old-DBA/2J mice.65 In a mouse model of AD using mutated 
APP transgenic mice, apoptosis of RGCs was also found to be 
associated with over-expression of Aβ.25 These data suggest 
that Aβ plays a role in apoptosis of RGCs, with or without 
elevated IOP. In addition, some studies suggest that ischemia 
could promote the deposition of Aβ in tissue by increasing 
the production from APP and through decreased cleaning via 
the blood vessels,66 indicating that similar mechanism might 
be involved in NTG. In retinal samples from patients with 
POAG or NTG, the immunoreactivity of advanced glycation 
end products and their receptor, RAGE, have been found, 
which suggested the process of aging was accelerated in 
POAG and NTG.67 
Flammer and Mozaffarieh summarized the pathogenesis 
of glaucomatous optic neuropathy.59 The causative factors 
in the mechanism of NTG in relation to neurodegenerative 
disease using the concept of neurovascular dysfunction are 
summarized below. The term neurovascular unit refers to a 
collection of different cells around blood vessels, including 
neurons, glia cells, and vascular cells. These cells come 
together to form a structural and functional integrated unit to 
maintain the balance of the microenvironment outside of the 
cells (Figure 1).60,66,68,69 In normal conditions, the neurovascu-
lar unit has the function of regulating OBF via the end-feet 
activity of astrocytes,70 the autoregulating blood vessels,59 and 
regulating some special molecules, such as nitric oxide (NO), 
Figure 1 Neurovascular dysfunction in the mechanism of NTG.
Notes: Neurovascular unit is a collection of different cells around blood vessels – including neurons, glia cells, and vascular cells – forming a structural and functional inte-
grated unit to maintain the normal balance of microenvironments. Neurovascular dysfunction includes the damage of BRBs, leading to the mal-transmission between blood 
vessels and the microenvironment around neurons. The damaging effects include extravasation, internal transportation of circulating toxin (ET-1, Aβ), release of inflammatory 
cytokines or antigens, etc, which will trigger retinal gliosis and lead to neural degeneration. 
Abbreviations: eT-1, endothelin-1; Aβ, amyloid-β; RGC, retinal ganglion cell; BRB, blood–retinal barrier; OBF, ocular blood flow; NTG, normal tension glaucoma.
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ET-1, etc.71 Other functions include controlling the exchange 
across the blood–brain barrier, immune surveillance, hemo-
static balance, and trophic function.66 Neurovascular dys-
function is characterized by multiple structural alterations 
associated with disruption of neurovascular unit functions. 
The first course or process of neurovascular dysregula-
tion is vascular dysfunction, consisting of vascular oxidative 
stress and inflammation, which reduces the OBF and thereby 
aggravates ischemia.60,72 The second course or process of neu-
rovascular dysregulation is damage of blood–retinal barriers 
(BRB), including protein extravasation,73 the transportation 
of Aβ across the blood vessel to tissue,74 and release of ET-1 
and matrix metalloproteinase 9.75,76 All of these factors could 
contribute to the degeneration of RGCs and to the release 
of inflammatory cytokines or antigens, which might trigger 
the immune response and could be the cause of the involve-
ment of the autoimmune mechanism.77 There is increasing 
evidence that indicates the presence of BRB damage in 
glaucoma, including NTG,78–81 where the BRB damage is also 
suggested to be a cause of optic disc hemorrhage.82 The third 
course or process of neurovascular dysregulation is gliosis. 
Reactivated glial cells, such as astrocyte, can release NO and 
TNF-α, provoking many deleterious signaling pathways that 
are involved in the neurodegeneration of glaucoma, which 
has been discussed in previous studies.77,83,84 The last course 
or process of neurovascular dysregulation is loss of trophic 
support. The condition of neurovascular dysfunction disrupts 
the bioactivity and signaling of growth factors, such as vascu-
lar endothelial growth factor and brain-derived neurotrophic 
factor, which has an impact on the normal function and 
survival of the cells in the neurovascular unit.85–88 
Apoptosis of RGCs from the extrinsic  
and intracellular signaling pathways
It is now generally accepted that apoptosis is the major 
pathway of RGC death in glaucoma.89 Both the extrinsic 
and intracellular pathways of apoptosis are involved in RGC 
death. The former pathway can be mediated via the death 
receptor of the TNF super-family on the cell membrane,89 and 
the latter is mediated by mitochondrion.90 The NTG-related 
models of transgenic mice are listed in Table 1. Some of the 
mutated genes or abnormally expressed proteins could affect 
the apoptosis of RGCs, and would therefore be involved in 
the mechanisms of NTG,26,27 although proof is needed. 
Thus, in regard to vascular dysfunction, one possible 
mechanism in NTG could be that which is summarized 
below and in Figure 1. The risk factors, such as vascular 
factors, aging-related factors, etc, disrupt the BRB leading to 
neurovascular dysfunction, which activates the response of 
endothelial cells and glial cells, and induces direct insult to 
neurons; then, more damaging factors could be released from 
the BRB into the microenvironment of the neurovascular unit 
to provoke an intracellular event, such as apoptosis, resulting 
in the degeneration of RGCs. A previous study91 summarized 
that neurodegeneration in glaucoma goes through two phases: 
direct damage to RGC and axons, and secondary damage by 
responses of nonneuronal cells. The secondary damage is 
considered to be the major cause of RGC loss in glaucoma.91 
Thus, it is reasonable to target the rescue of the vascular from 
dysfunction and control of gliosis. Doing so would maintain 
the microenvironment of the neurovascular unit, which could 
be the essential therapeutic mechanism for NTG.
The current concepts regarding  
the relationship between  
NTG and HTG
The commonly held categorization of NTG is as a subtype of 
POAG.1 However, there is evidence to show the distinction 
between NTG and POAG.3,30,92 Results for current investi-
gations have offered both similarity and difference between 
NTG and POAG.3,30,92
Clinically, NTG was initially described from clinical 
features of glaucoma. Thus, similar to POAG, the main man-
agement for NTG is to reduce IOP,93 which has been shown to 
slow the progress of the disease. Some studies on the cornea 
showed the corneal thickness of NTG patients is thinner than 
normal, resulting in the lower IOP reading, which suggested 
that relatively high IOP status may present in NTG patients. 
Thus, the condition in NTG is similar to the conditions in 
POAG after adjusting the IOP reading according to the rela-
tive corneal thickness.94,95 However, there is other evidence 
observed in NTG patients that differs from POAG patients, 
eg, the incidence of optic disk hemorrhage is higher, the 
decrease of retinal nerve fiber layer is earlier, and the shape of 
defect of VF is different.96 Although, these observations were 
controversial,71 it still hints at the significance of the distinc-
tion of NTG under its phenotype. Most researchers believe 
that the causative factor is the alteration of OBF.3,41,97 Strong 
evidence showed the presence of vascular problems or abnor-
mal perfusion in NTG patients.93 Other evidence suggested a 
populational relationship of systemic vascular diseases with 
NTG patients,98,99 which was not shown in POAG patients. 
With regard to pathophysiological mechanisms, the 
similarity and difference between NTG and POAG still 
coexist. Based on the vascular theory of glaucoma, if there 
is no elevation of IOP, other causative factors related to 
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vascular abnormality could lead to glaucomatous change.41,54 
IOP-independent factors play an important role in the 
mechanism of NTG, which is different from the dominant 
role of high IOP for the mechanical mechanism in the 
development of POAG.59 However, basic research regards 
both of them as neurodegenerative diseases, where there is a 
similar signaling pathway of apoptosis resulting in the loss of 
RGCs.59,100 In addition, similar cellular or protein responses, 
such as gliosis, ET-1 increase, glutamate toxicity, oxidative 
stress, etc, are involved in the mechanism.101,102 Even similar 
gene mutation is found both in NTG and POAG based on 
the epidemiological evidence.103–105 Both NTG and POAG 
are prevalent in senile populations.61,93 Some studies showed 
evidence that the anti-Alzheimer agents exhibit benefit 
to POAG patients.106,107 Thus, presently, more and more 
researchers consider glaucomas as a group of aging-related 
disease similar to neurodegenerative disease in the central 
nervous system.108,109 
Up to now, because the definite mechanism of POAG is 
still unclear, it is not the appropriate time to separate com-
pletely NTG from POAG. Maybe the initial causative factor is 
different. It is likely that NTG is due to vascular abnormality 
and POAG is due to increased IOP. However, neurodegenera-
tion in the retina and optic axons is the common final pathway 
in both diseases. After all, the mechanism and the therapy for 
both diseases are clearly related to each other.
From the above depiction, in the research field of NTG, 
there are many issues that need to be further investigated, for 
example, gene-scanning works of demography in different 
races aiming to discover more genetic characteristics of 
NTG patients. Then, more lines of transgenic mice should 
be used to mimic the disease course of NTG to provide more 
chances to discover some specific mechanisms and thera-
peutic interventions in vivo. Clarification of the mechanism 
is proposed to find some special biomarkers, which will be 
beneficial to the early diagnosis of NTG in the clinical setting. 
In addition, more attention should be paid to the treatments 
concerning antiaging and blood vessel protection as a kind 
of neuroprotection in NTG. 
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